WEE1 and cancer: Interestingly, Wee1 inhibition in clinical trials as a single agent therapy has shown preferential responsiveness in uterine and ovarian tumours, specifically harbouring BRCA mutations [142,143,144,145]; however, only one study investigating radiosensitive effects in these cancer types has been explored and was terminated early due to limiting toxicities (NCT03345784).